Safety in pediatric sedation relies on strict guidelines and monitoring, so let's learn how providers utilize pharmacological ...
Next-Generation Novasight Hybrid™ System Submitted to U.S. FDA for 510(k) Clearance U.S. and European Class 1A Guidelines Reinforce Growing ...
Emirates News Agency on MSN
DoH, Ma’an open applications for 2026 healthcare research and innovation fund
The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector, in collaboration with the Authority of Social Contribution – Ma’an, has opened applications for the 2026 edition of ...
Nadeem Anam, Associate Director, Medical Technology Association of India (MTaI) shared his valuable inputs on various aspects ...
Curious to know which obesity stories grabbed the attention of readers this year? Medscape Medical News develops a list of ...
Contemporary cardiology faces a paradox: unprecedented technological capability coincides with declining scientific curiosity ...
A nationwide survey by the Alzheimer’s Association in 2025 found close to 4 in 5 Americans 45 and older want to know if they have Alzheimer’s before symptoms appear. And 91% said they would take a ...
Every winter, India’s air pollution crisis returns with stark visibility. Smog blankets Delhi and much of the Indo-Gangetic Plain, flights are disrupted, schools shut, and emergency health advisories ...
Next-Generation Novasight Hybrid System Submitted to U.S. FDA for 510(k) Clearance U.S. and European Class 1A Guidelines Reinforce Growing Adoption of Image-Guided PCIPeer-Reviewed Publications Highli ...
Live Science on MSN
Scientists are developing a 'self-driving' device that helps patients recover from heart attacks
Live Science spoke with Dr. Joe Alexander of NTT Research about "digital twins" and the development of an autonomous device ...
4don MSN
Their baby had little chance of survival. Then Texas Children's offered a novel, in-utero solution.
A Dallas couple turned to Texas Children's Hospital for a complex and high-risk procedure to insert a stent in their son's ...
The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results